Engflag

Iroz

Quick links to important sections

Iroz

Iroz_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Iroz

What is Iroz?

Iroz is a medicinal product containing the active substance ferric carboxymaltose. It is categorized as an iron replacement therapy, specifically designed for intravenous administration. This medication is used to replenish iron stores in the body when oral iron preparations are ineffective, cannot be used, or when there is a clinical need to deliver iron rapidly to the iron stores.

Composition and Mechanism

The active ingredient, ferric carboxymaltose, consists of a polynuclear iron(III)-hydroxide core stabilized by a carbohydrate shell. This structure is designed to provide a controlled release of iron to the iron-binding and iron-storage proteins in the body, such as ferritin and transferrin. By delivering iron directly into the bloodstream, the medication bypasses the gastrointestinal absorption process, which can be a limiting factor in some patients.

Therapeutic Purpose

The primary goal of treatment with Iroz is to address iron deficiency. Iron is a critical component of hemoglobin, the protein in red blood cells responsible for carrying oxygen throughout the body. It is also essential for several other physiological processes, including muscle metabolism and the function of various enzymes. When iron levels are insufficient, the body cannot produce enough healthy red blood cells, which may lead to iron deficiency anemia or other systemic symptoms associated with low iron levels.

Clinical Application

Iroz is utilized in various clinical settings where iron deficiency has been diagnosed. This includes cases where patients have a known intolerance to oral iron or where inflammatory conditions of the gastrointestinal tract make oral supplementation unsuitable. It is also used when iron stores must be replenished quickly, such as in the management of iron deficiency associated with chronic kidney disease, heart failure, or following significant blood loss.

Regulatory References

  1. MedlinePlus Folic Acid Summary

What side effects are possible with Iroz?

The safety profile for Iroz, which contains the active ingredient Folic Acid, is based on the classification of adverse events documented in official governmental regulatory sources.

Officially Documented Adverse Reactions

Adverse reactions associated with Folic Acid are generally considered rare in regulatory documentation, falling across several System-Organ Classes. These effects are primarily categorized as:

System-Organ Class Associated Adverse Reactions
Immune System Disorders Hypersensitivity reactions, including allergic sensitization.
Gastrointestinal Disorders Disturbances such as nausea, abdominal distension, and flatulence.
Skin and Subcutaneous Tissue Disorders Skin rash, itching (pruritus), and reddening (erythema).

Serious adverse reactions documented in official labeling include anaphylaxis (a severe, generalized allergic response). Other serious concerns relate to the risk of neurological damage (see below).

Population-Specific Safety Considerations

The most significant restriction documented in regulatory labeling involves patients with untreated Vitamin B12 deficiency (such as pernicious anemia). Folic Acid must not be given alone in this context, as it may correct the blood abnormalities while allowing irreversible neurologic damage to progress without obvious hematological warning signs. This administration alone is officially defined as improper therapy.

Additionally, safety notes indicate that Folic Acid may antagonize the anticonvulsant action of certain medications, such as phenytoin, a concern specified in regulatory information for patients with epilepsy. Prolonged Folic Acid therapy is also documented to potentially lead to decreased Vitamin B12 serum levels.

Overdose and Emergency Response

Overdose and When to Seek Help

Iroz (osilodrostat) is a medication that works by lowering cortisol levels. An overdose or taking significantly more than the prescribed amount is expected to result in an exaggeration of this primary effect, leading to severe hypocortisolism or adrenal insufficiency.

Adrenal insufficiency is a potentially life-threatening condition that requires immediate medical intervention. Therefore, if an overdose is suspected, urgent medical attention must be sought immediately.

Overdose-Related Symptoms and Conditions
Symptoms of severe hypocortisolism may include nausea, vomiting, stomach pain, extreme tiredness or fatigue, loss of appetite, dizziness, and low blood pressure (hypotension).
The physiological risk extends to life-threatening adrenal insufficiency.

Required Emergency Actions

If an overdose is suspected, the regulatory guidance states that the drug must be discontinued. Treatment should be focused on preventing and managing hypocortisolism. This typically requires the administration of glucocorticoid replacement therapy and, if necessary, mineralocorticoid replacement therapy.

Contacting a poison control center or seeking emergency medical care is critical for immediate clinical management. Prompt action is necessary to address the severe endocrine imbalance resulting from excessive medication exposure.

Therapeutic Uses of Iroz

Iroz, which contains Folic Acid (Vitamin B9), is applied across domains where additional symptomatic support is needed, playing a role in managing two distinct, clinically significant situations. It is commonly used to help with treating and reversing folate deficiency anemia, a condition often characterized by megaloblastic changes in red blood cells.

Quick Fact: Relief for Symptoms Related to Systemic Imbalance

The therapy contributes to easing the overall symptom burden, supporting patients with fatigue, profound lethargy, and oral manifestations like a sore tongue.

Therapeutic Use Cases

The medication is considered relevant for managing deficiency anemia, specifically macrocytic or megaloblastic anemia; Neural Tube Defect (NTD) prevention in the developing fetus; and adjunctive support for patients on certain drug therapies (e.g., methotrexate). The preparation helps address symptom clusters that create noticeable physiological strain and interference with daily stability. The benefit may assist with maintaining functional stability during difficult episodes, particularly in women capable of becoming pregnant, where the context involves general preventive care.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Iroz?

The population eligibility for Iroz (Folic Acid) is defined by official regulatory documentation, focusing on conditions that necessitate restricted use or absolute prohibition.

Populations and Conditions

Classification Regulatory Statement Eligible Populations
Contraindicated Use is contraindicated in patients with known hypersensitivity to Folic Acid or any component of the formulation. It is also contraindicated as monotherapy for megaloblastic anemias resulting from Vitamin B12 deficiency (e.g., Pernicious Anemia), as this may mask hematological symptoms while allowing severe neurological damage to progress. General adults, children, and older adults are eligible for treating documented folate deficiency. Use is allowed and recommended during pregnancy (US FDA Category A) and lactation.
Restricted Use Use is restricted in cases of undiagnosed anemia until Vitamin B12 deficiency is officially ruled out. The medicine is generally not suitable for patients with certain malignancies unless concurrent folate deficiency is also present.
Age and Function Use is established across all age groups, including pediatric and geriatric patients. Individuals undergoing haemodialysis are an eligible group with specific, increased requirements for the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Iroz, which contains Folic Acid, has several officially documented interaction patterns primarily categorized by their effect on drug efficacy or metabolism. Regulatory documents formally state that Folic Acid may antagonize the anticonvulsant action of medicines like Phenytoin, potentially reducing seizure control. It is also documented to potentiate the pharmacologic effects and associated toxicity of chemotherapy agents such as Fluorouracil (5-FU).

Documented Interaction Constraints

Substance / Category Official Interaction Statement
Antifolate Agents (e.g., Methotrexate, Trimethoprim) Folic Acid may reduce the anti-folate efficacy of these medicines.
Anticonvulsants (e.g., Phenobarbital, Primidone) These agents may reduce serum and red cell folate levels by interfering with metabolism.
Cholestyramine / Antacids Co-administration may reduce Folic Acid absorption, requiring timing separation of two to six hours.
Alcohol Consumption is documented to interfere with folate metabolism and increase its elimination.

Regulatory Restriction

Folic Acid is formally contraindicated for the sole treatment of undiagnosed megaloblastic anemia where Vitamin B12 deficiency has not been ruled out. This restriction exists because Folic Acid can mask the hematological signs of B12 deficiency while allowing irreversible neurological damage to progress.

Mechanism of Action

Iroz is a bisphosphonate compound that selectively accumulates within bone tissue by binding to the crystalline structure of hydroxyapatite. This binding serves as a localized storage mechanism, concentrating the drug at sites of bone remodeling, which are regions undergoing acidification due to active osteoclastic resorption. The resulting acidic microenvironment facilitates the drug's uptake into osteoclasts via fluid-phase endocytosis.

Once internalized into the osteoclast cytosol, Iroz functions as a direct inhibitor of the mevalonate pathway enzyme farnesyl pyrophosphate synthase (FPPS). This molecular interaction prevents the synthesis of isoprenoid lipids, such as farnesyl pyrophosphate, which are essential for the post-translational prenylation of small GTPases, including the Rho and Rac families. The resulting lack of prenylation inhibits the proper membrane localization and activity of these GTPases. This intracellular cascade disrupts the osteoclast's cytoskeletal organization and its ruffled border structure, impairing its ability to adhere to the bone surface and secrete acid. The final downstream consequence is the programmed cell death, or apoptosis, of the osteoclast, leading to a system-level modulation characterized by a substantial reduction in bone resorption.

Dosage and Administration Information

Iroz (Folic Acid) administration is governed by standardized guidelines focusing on the route, dosage, frequency, and duration of use.

The preferred method of administration is oral, utilizing tablets or solutions/syrups, as Folic Acid is well absorbed through the digestive tract. The parenteral routes, including intravenous (IV), intramuscular (IM), or subcutaneous (SC) injection, are reserved for specific patients unable to absorb oral doses, such as those with severe malabsorption.

The standard therapeutic dose for adults is established at 1 mg once daily. Certain high-requirement states, such as tropical sprue or high-risk pre-conception planning, may necessitate a higher daily dose of up to 5 mg. The most common schedule is once daily, and oral forms can be taken with or without food. Liquid forms require a calibrated measuring device to ensure accurate dosing.

Therapy often follows a structured sequence: an initial higher dose regimen transitions to a maintenance dose after clinical stability is achieved. The standard duration for deficiency correction is typically established as several months, such as four months. If a dose is missed in a once-daily regimen, the standard protocol is to take it only if the next scheduled dose is not imminent; otherwise, the missed dose should be skipped. A double quantity must not be taken. Official labeling also specifies tailored use for certain populations, including a higher 5 mg daily dose for high-risk pre-conception planning.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Focus and Mechanism

Research has explored the hypothesis that the compound was hypothesized to interact with certain receptors in the nervous system. Studies examined this potential action using in vitro models and animal subjects to understand potential biological interactions.

Efficacy Data from Key Trials

Several randomized, controlled trials (RCTs) and non-controlled open-label extensions have investigated whether participants experienced reductions in symptoms across various disease subtypes.

  • Phase II Trials: Early-stage research included small studies that assessed the effects of varying quantities of the compound. These initial findings explored whether the drug affects measures of quality of life.
  • Phase III Trials: Larger trials focused on the primary outcome of symptom change. Research has explored whether the drug is associated with changes in pain compared to placebo. One study examined the time to onset of effect and observed initial changes during the early phase of administration.
  • Combination Therapy: Studies compared the effects of the combination treatment with monotherapy alone. The primary endpoint for these studies was a change in the frequency of symptomatic events over a six-month period.

Safety and Tolerability Profile

Safety and tolerability were primary endpoints in several trials. Commonly observed adverse events were reported to be generally transient. Study documentation noted that these events were temporary and infrequently led to participant discontinuation.

Special Populations and Long-term Data

Researchers have studied the drug’s observed effect on inflammation and evaluated its use in participants with severe disease. However, Clinical trials excluded participants with pre-existing heart conditions. Data regarding use beyond one year are limited, and the complete long-term profile continues to be studied.

Frequently Asked Questions (FAQ)

Common questions about Iroz (FAQ)

Q: Is Iroz available over the counter?

The availability of Folic Acid varies by dose and location. While lower-strength doses are available without a prescription in some countries, the higher strength doses used for specific therapeutic purposes often require a prescription.

Q: What kind of stomach issues does Iroz help with?

The general purpose of Iroz is to support the body’s ability to perform essential cellular functions, primarily by supporting blood formation. It is officially classified as a Hematinic Agent and is not indicated as a primary treatment for specific stomach issues.

Q: Can Iroz be taken long-term?

The use of Iroz for correcting a deficiency is typically established for a period of several months. Official guidance also describes a transition to a maintenance dose after initial stability is achieved, suggesting ongoing use is determined by the underlying requirement. Studies have examined the drug's profile, but data regarding use beyond one year are limited.

Q: How quickly does Iroz start to work?

Research has examined the time to onset of effect based on clinical markers of correction. The start of new red blood cell formation is associated with a timeframe of several days to weeks after starting the compound.

Q: What is the maximum duration for Iroz treatment mentioned in official documents?

Official documents typically establish the standard duration for deficiency correction as several months, often cited as four months. A definitive, formal maximum duration is not specified, but studies examining long-term use have limited data beyond one year.

Q: Is Iroz known by any other brand names?

The active ingredient, Folic Acid, is often included in various combination products in different markets. Examples of brand names for these combination products that contain Iroz include Irozorb Plus or Irospan.

Q: Is it okay to take Iroz before bed?

The regulatory guidance for Iroz states that it is typically taken once daily and can be taken with or without food. Official documents do not specify a particular time of day for administration.

Q: Does Iroz interact with supplements or vitamins?

Official product information specifies a critical interaction with untreated Vitamin B12 deficiency, as using Iroz alone may mask the blood abnormalities while allowing irreversible nerve damage to continue. The medicine itself is often formulated as a combination product with other micronutrients.

Q: Why is Iroz used with antibiotics sometimes?

Iroz, as Folic Acid, is sometimes used as part of a combination product that includes other vitamins like B12 or minerals like Iron. Separately, official documents note that Folic Acid may reduce the anti-folate effectiveness of certain medicines, including antifolate agents.

Q: Is Iroz safe for people with heart conditions?

While official documents do not list heart conditions as a contraindication or restriction for the use of Iroz, research overviews indicate that clinical trials for the compound excluded participants with pre-existing heart conditions.

Q: Is it safe to take Iroz if I have kidney problems?

Official guidance describes individuals undergoing haemodialysis as a population that may have specific, increased requirements for the medicine.

Q: Why do doctors prescribe Iroz for ulcers?

Iroz, as a Hematinic Agent, is officially indicated for conditions related to supporting blood formation and cellular maintenance. It is not documented in regulatory information as a primary treatment for ulcers.

Q: Is Iroz addictive?

The compound is pharmacologically classified as a water-soluble vitamin. According to regulatory sources, this type of medicine is not documented as having potential for addiction or dependence.

Q: Will I have withdrawal symptoms if I stop taking Iroz?

Regulatory guidance surrounding missed doses and the standard duration of therapy does not include warnings or discussion about withdrawal symptoms upon stopping the use of the medicine.

Q: Is it common to feel tired while taking Iroz?

When reviewing officially documented adverse reactions, tiredness (fatigue) is not listed among the commonly observed effects associated with this medicine.

Q: Are headaches a known side effect of Iroz?

Headaches are not listed among the officially documented adverse reactions in the safety profile for Iroz.

Q: Does Iroz cause joint pain?

Official documents outlining the drug's safety profile do not list joint pain among the reported adverse reactions associated with the medicine.

Q: Can Iroz affect my sleep?

Regulatory sources detailing the known side effects do not include effects on sleep or insomnia among the documented adverse reactions associated with the medicine.

Q: Can Iroz make me feel dizzy?

The official documents that classify the drug's adverse reactions do not list dizziness among the reported effects of the medicine.

Q: Can Iroz cause low magnesium levels?

When examining the officially documented adverse reactions, low magnesium levels (hypomagnesemia) are not listed among the side effects associated with this medicine.

Q: Can Iroz change the color of my stool?

Official documents that list the adverse reactions for Iroz do not include a change in stool color among the documented side effects.

Q: Is there a link between Iroz and bone fractures?

Official documents detailing the safety and adverse reaction profile of Iroz do not list an association with bone fractures.

How should Iroz be stored and disposed of?

How to Store and Dispose of Iroz? (Folic Acid)

The storage and disposal of Iroz (Folic Acid) must adhere strictly to regulatory requirements to maintain its stability and ensure safety.

Official Storage Conditions

  • Temperature and Protection: The medicine must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), and must not be stored above 30 C (86 F). It requires protection from light and moisture. Liquid formulations must also be kept from freezing.
  • Container and Safety: Iroz should be kept in a well-closed container in its original packaging. It must be stored out of the sight and reach of children.

Disposal

Unused or expired Iroz must be disposed of in accordance with local requirements for pharmaceutical waste. Do not save outdated or unneeded medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Iroz found in:

A-Z Index: